Shanghai Raas Blood Products | Sustainability Performance
Develops and markets plasma-based biopharmaceutical products.
1988
China
1,001 - 5,000 employees
Biotechnology
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#10785
Overallⓘ#770
in Chinaⓘ#231
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Water ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Laggard
Laggard
Controversy level
- Shanghai RAAS Blood Products Co Ltd, Chinese plasma/blood products major (Grifols affiliated via JV), has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of plasma product quality at multiple Chinese collection facilities, plus the contested 2024 sustained share price volatility amid Chinese plasma market normalization affecting Chinese institutional shareholders.
